AbbVie | ABBV

Stock Price
165.54
Daily Change
3.42 2.11%
Monthly
1.91%
Yearly
22.23%
Q2 Forecast
159.72
Peers Price Chg Day Year Date
Eisai 7,080.00 115.00 1.65% -27.76% Jun/05
AbbVie 165.54 3.42 2.11% 22.23% Jun/05
Abbott 102.73 -0.66 -0.64% -0.99% Jun/05
ALKERMES 24.06 0.41 1.73% -18.33% Jun/05
Amgen 308.86 1.47 0.48% 39.62% Jun/05
AstraZeneca 12,516.00 112.00 0.90% 5.78% Jun/05
Biogen 236.66 2.87 1.23% -21.06% Jun/05
BioMarin Pharmaceutical 78.56 -0.53 -0.67% -14.36% Jun/05
Bristol-Myers Squibb 41.16 -0.60 -1.44% -37.62% Jun/05
Gilead Sciences 64.07 -0.04 -0.06% -15.92% Jun/05
GlaxoSmithKline 1,650.50 35.50 2.20% 18.62% Jun/05
J&J 146.33 -1.51 -1.02% -7.57% Jun/05
Eli Lilly 833.91 0.88 0.11% 88.21% Jun/05
Medtronic 81.80 -1.52 -1.82% -2.15% Jun/05
Merck 129.64 1.06 0.82% 17.84% Jun/05
Neurocrine Biosciences 135.22 1.74 1.30% 44.07% Jun/05
Novartis 94.50 1.77 1.91% 4.40% Jun/05
Pacira 30.80 0.28 0.92% -20.10% Jun/05
Pfizer 29.37 -0.08 -0.27% -24.01% Jun/05
Perrigo 26.63 -0.53 -1.93% -20.63% Jun/05
Ultragenyx Pharmaceutical 41.75 0.83 2.03% -18.54% Jun/05
Regeneron Pharmaceuticals 1,011.33 17.85 1.80% 35.18% Jun/05
Roche Holding 236.10 1.90 0.81% -19.19% Jun/05
Sanofi 90.69 0.42 0.47% -5.89% Jun/05
UCB 129.50 1.75 1.37% 54.20% Jun/05
United Therapeutics 277.36 4.17 1.53% 26.72% Jun/05
Vertex Pharmaceuticals 482.13 7.19 1.51% 45.92% Jun/05
Zoetis 176.02 4.03 2.34% 3.46% Jun/05

Indexes Price Day Year Date
US500 5341 49.87 0.94% 24.68% Jun/05

AbbVie traded at $165.37 this Wednesday June 5th, increasing $3.25 or 2.00 percent since the previous trading session. Looking back, over the last four weeks, AbbVie gained 1.80 percent. Over the last 12 months, its price rose by 22.11 percent. Looking ahead, we forecast AbbVie to be priced at 159.72 by the end of this quarter and at 156.81 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.